Hepcidin levels and their determinants in different types of myelodysplastic syndromes by V. Santini et al.
Hepcidin Levels and Their Determinants in Different
Types of Myelodysplastic Syndromes
Valeria Santini1., Domenico Girelli2*., Alessandro Sanna1, Nicola Martinelli2, Lorena Duca3, Natascia
Campostrini2, Agostino Cortelezzi4, Michela Corbella2, Alberto Bosi1, Gianluigi Reda4, Oliviero Olivieri2,
Maria Domenica Cappellini3
1Hematology Unit, AOU Careggi, University of Florence, Florence, Italy, 2Department of Medicine, Section of Internal Medicine, University of Verona, Verona, Italy,
3Department of Internal Medicine, ‘‘Ca` Granda’’ Foundation IRCCS, University of Milan, Milan, Italy, 4Hematology Unit 1, ‘‘Ca` Granda’’ Foundation IRCCS, University of
Milan, Milan, Italy
Abstract
Iron overload may represent an additional clinical problem in patients with Myelodysplastic Syndromes (MDS), with recent
data suggesting prognostic implications. Beyond red blood cells transfusions, dysregulation of hepcidin, the key iron
hormone, may play a role, but studies until now have been hampered by technical problems. Using a recently validated
assay, we measured serum hepcidin in 113 patients with different MDS subtypes. Mean hepcidin levels were consistently
heterogeneous across different MDS subtypes, with the lowest levels in refractory anemia with ringed sideroblasts (RARS,
1.43 nM) and the highest in refractory anemia with excess blasts (RAEB, 11.3 nM) or in chronic myelomonocytic leukemia
(CMML, 10.04 nM) (P= 0.003 by ANOVA). MDS subtypes remained significant predictors of hepcidin in multivariate analyses
adjusted for ferritin and transfusion history. Consistently with current knowledge on hepcidin action/regulation, RARS
patients had the highest levels of toxic non-transferrin-bound-iron, while RAEB and CMML patients had substantial elevation
of C-Reactive Protein as compared to other MDS subtypes, and showed lost of homeostatic regulation by iron. Growth
differentiation factor 15 did not appear as a primary hepcidin regulator in this series. If confirmed, these results may help to
calibrate future treatments with chelating agents and/or hepcidin modulators in MDS patients.
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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group
of clonal stem cell disorders characterized by dysplastic and
ineffective hematopoiesis, peripheral cytopenias often including
severe anemia, and a variable risk of progression to acute
myleogenous leukemia (AML) [1].
Iron overload frequently occurs in MDS patients [2], with
recent data suggesting an impact on both overall and leukemia-
free survival [3]. Though prolonged red blood cells (RBC)
transfusion therapy appears the main contributor, many patients
appear to develop iron overload at an early stage of the disease,
before the onset of transfusions [4]. It has been postulated that an
altered production of hepcidin, the recently discovered key
hormone regulating iron homeostasis [5], may play a role at this
regard [6]. Hepcidin is a small peptide that acts by binding to
ferroportin, its receptor highly expressed on the membrane of cells
involved in iron handling like iron absorbing duodenal enterocytes
and macrophages recycling senescent erythrocytes [7]. Ferropor-
tin, the only known cellular iron exporter in vertebrates, is
internalized and degraded after hepcidin binding [8], which results
in blocking both dietary iron absorption and the release of iron
from macrophages. The regulation of hepcidin is complex and
mediated by different stimuli with opposing effects [5,9]. Increased
hepatic and plasma iron homeostatically induce hepcidin synthe-
sis, as does inflammation, while erythropoietic activity suppresses
the hormone production [9]. The latter is finalized to increase iron
supply for erythropoiesis through enhanced iron absorption and
release from macrophages. Such effect becomes particularly
important in diseases with ineffective erythropoiesis, where
erythrocyte precursors massively expand but undergo apoptosis
rather than maturing. Growth differentiation factor 15 (GDF-15),
a protein produced by erythroid precursors, has been proposed to
be a major hepcidin suppressor in b-thalassemia [10], but data in
other conditions with ineffective erythropoiesis are less conclusive
[11].
Until recently, clinical studies on hepcidin in humans have been
hampered by problems in the development of reliable assays
[12,13]. Regarding MDS, only scanty and conflicting data based
on first generation semi-quantitative measurement of urinary
hepcidin have been reported [14,15]. We used a recently validated
and improved Mass-Spectrometry based method to analyze serum
hepcidin levels in MDS patients, also focusing in trying to
elucidate its determinants.
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Methods
Patients
Patients and controls were enrolled at Internal Medicine and
Hematology Units in Verona (Azienda Integrata Ospedaliera-
Universitaria), Florence (Ospedale Careggi) and Milan (Policli-
nico), all in Italy. One hundred and thirteen MDS patients (mean
age 72.869.2 years; 68.1% males) were included. To be enrolled
in this study, patients had to be previously untreated or treated
only with transfusions. Patients treated at any time with iron
chelating agents were excluded. After careful evaluation of
transfusion history, patients were defined transfusion-dependent
or transfusion-independent according to International Working
Group (IWG) criteria [16]. Reliable data in this sense were
available for 107/133 patients. MDS subtypes were classified
according to World Health Organization (WHO) [17], and
stratified for prognosis according to International Prognostic
Scoring System (IPSS). To do a comparison with respect to serum
hepcidin levels and the hepcidin/ferritin ratio (see below), a group
of fifty-four healthy individuals (61.1% males) with rigorous
definition of normal iron status as previously described in details
[18,19], were used as controls. The protocol of this observational
study was approved by the Ethical Committee of the Azienda
Integrata Ospedaliera Universitaria of Verona, and all subjects
gave written informed consent.
Biochemical Assays
Blood samples were obtained early in the morning after
overnight fasting, immediately centrifuged, and serum was stored
at 280uC in aliquots to avoid multiple freeze-thaw cycles. Serum
iron, transferrin, ferritin, and C-Reactive Protein (CRP) were
measured using routine standard laboratory assays.
Serum hepcidin was measured by Surface-Enhanced Laser
Desorption/Ionization Time-Of-Flight Mass Spectrometry (SELDI-
TOF MS), using a synthetic hepcidin analogue (Hepdicin-24,
Peptides International, Louisville, KY) as an internal standard, as
previously described [19], with recent technical advances [20]. The
ratio between hepcidin and ferritin, which reflects the homeostatic
ability of hepcidin to increase as a response to increased body iron
was calculated as previously described [21].
Serum non-transferrin-bound iron (NTBI) was evaluated by
chromatographic method as previously described [22]. Briefly,
450 ml of serum was added to 50 ml of nitrilotriacetic acid 800 mM
(pH 7.0) and allowed to stand for 15 min. The solution was
ultrafiltered using an Amicon Centricon 30 microconcentrator
and the ultrafiltrate (20 ml) was injected directly into the high
performance liquid chromatography (HPLC) system with a
titanium pump module (Perkin Elmer S200, Boston, MA, USA).
The HPLC column used for the determination of NTBI had the
following characteristics: Nova-Pak C18, 4 mm, 3.96150 mm,
reversed-phase column produced by Waters (Wexford, Ireland).
The chromatographic conditions were the following: Flow rate
1.5 ml/min; mobile phase isocratic containing 20% acetonitrile
and 80% sodium phosphate buffer, 5 mM (pH 7.0) containing
3 mM CP22; visible detection, 450 nm. A standard curve was
generated by injecting different concentrations of iron prepared in
a 100-fold excess of NTA. The standards were routinely run at 0
to 10 mM, although absorbance was linear up to 40 mM. Under
these conditions, the 0 mM standard corresponds to 80 mM of
NTA. The addition of 80 mM of NTA to the serum of normal
individuals always results in negative NTBI values. Normal
individuals always have negative NTBI values because blank is
formed by water and nitrilotriacetic acid; water per se contains
small amounts of iron that is not bound by transferrin, whereas in
samples, transferrin, which is not completely saturated, captures
some iron from the ferritin-nitrilotriacetic acid complex [23].
Serum GDF-15 was determined using a commercially available
Duo-Set enzyme-linked immunosorbent assay (ELISA) according
to manufacturer’s indications (R&D Systems, Abingdon, Oxford-
shire, UK).
Serum erythropoietin (EPO) was determined using a commer-
cially available radioimmunoassay (EPO-Trac 125I) kit according
to manufacturer’s indications (DiaSorin, Stillwater, Minnesota,
USA).
Statistical analyses
All calculations were performed using SPSS 17.0 software (SPSS
Inc., Chicago, IL, USA). As many of the continuous variables of
interest, including serum hepcidin, ferritin, GDF-15, and EPO,
showed a non-Gaussian distribution, their values were log-
transformed and expressed as geometric means with 95%
confidence intervals (CIs). Quantitative data were analysed using
the Student’s t test or by analysis of variance (ANOVA) with
polynomial contrast for linear trend, when appropriate. Qualita-
tive data were analyzed with the x2 test and with x2 analysis for
linear trend, when appropriate. Correlations between quantitative
variables were assessed using Pearson’s coefficient. Independent
determinants of serum hepcidin levels were assessed at first in a
linear regression model estimating b-coefficients including all the
variables significantly correlated with hepcidin at univariate
analysis (e.g. ferritin, CRP), as well as age, gender, and
presence/absence of the diagnosis of MDS. Thereafter, aiming
to evaluate the potential heterogeneity in iron/hepcidin homeo-
stasis among the different types of MDS, the latter were codified as
dummy variables in linear regression models, adjusted at first for
sex, age, history of blood transfusion, and ferritin levels (model 1),
then adding CRP levels (model 2). To evaluate the different degree
of correlation between hepcidin and ferritin among the different
types of MDS, data were analyzed in a general linear model by
means of the F test for slopes. Two-sided p values,0.05 were
considered statistically significant.
Results
MDS patients versus controls
Table 1 shows the main characteristics and iron biochemical
parameters including serum hepcidin of the whole MDS
population as compared with the control group. Controls were
matched for gender (predominantly males), but were significantly
younger than MDS patients. Recent data from our laboratory in a
large population study have shown that serum hepcidin levels are
consistently stable in males over a wide age range (18–90 years)
[24]. Nevertheless, all multivariate analyses on serum hepcidin
levels were adjusted for gender. As shown in Table 1, biochemical
markers of iron overload (namely serum ferritin and transferrin
saturation), as well as CRP levels, were significantly higher in
MDS patients as compared to controls. In the whole MDS
population serum hepcidin levels were slightly higher than in
controls, but this difference did not reach the statistical
significance. Nevertheless, the hepcidin/ferritin ratio was signifi-
cantly lower in the whole MDS population as compared to
controls. As regards to serum GDF-15, we could not directly
measure this protein in controls, but levels in MDS patients
(4,422 pg/ml, 95% CIs 3,591–5,445) were markedly higher than
the manufacturer’s reference range (641 pg/ml, 95% CIs 401–
881). The same was true also for serum NTBI and EPO levels
(showed in Table S1).
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Transfusion dependent versus transfusion independent
MDS patients
Biochemical parameters of MDS patients stratified according to
the presence or absence of transfusion dependence are shown in
Table S1. As expected, transfusion dependent (TD) MDS patients
had significantly higher levels of serum ferritin and transferrin
saturation as compared to transfusion independent patients.
Notably, serum hepcidin levels were significantly higher in TD
MDS patients as compared to either controls or non-TD patients,
but the hepcidin/ferritin ratio was similar in TD and non-TD
MDS patients. TD MDS patients had also significantly higher
levels of serum NTBI, GDF-15, and EPO as compared to non-TD
patients.
MDS patients stratified according to different WHO
subtypes
Table 2 shows the clinical and biochemical characteristics of the
MDS patients stratified according to the WHO classification.
Serum hepcidin levels showed a significant variability across the
different MDS subtypes (P = 0.003 by ANOVA), with the lowest
values in patients with refractory anemia with ringed sideroblasts
(RARS) and the highest values in subjects with refractory anemia
with excess blasts (RAEB) and in patients with chronic myelo-
monocytic leukemia (CMML). The hepcidin/ferritin ratio (also
showed in Figure S1) was also markedly heterogeneous across the
different MDS subtypes. It was remarkably lower not only in
RARS but also in patients with the 5q- syndrome, while CMML
patients showed the highest values (P = 0.003 by ANOVA). Of
note, patients with RARS and with the 5q- syndrome also
appeared as the most iron overloaded, as suggested by the trend
toward higher levels not only of serum ferritin, but also of serum
transferrin saturation (P= 0.048 by ANOVA) and serum NTBI.
As regards to serum GDF-15 levels, they were consistently
homogeneous across the different MDS subtypes (P = 0.976 by
ANOVA). GDF-15 did not correlate at all with hepcidin levels
(r =20.07; P= 0.48). On the contrary, CRP levels were signi-
ficantly heterogeneous in different MDS subtypes (P = 0.008 by
ANOVA), with the highest values in patients with RAEB, CMML
and in those unclassified. Table S2 shows the biochemical
parameters in MDS patients stratified according to the IPSS.
Homeostatic control of hepcidin by iron
To explore the degree of preservation of the homeostatic control
of hepcidin by iron, we performed a set of general linear models.
As shown in Figure 1A, when considering the MDS population as
a whole, the positive correlation between hepcidin and ferritin was
relatively conserved, though the hepcidin/ferritin ratio was lower
than in controls suggesting a relatively blunted response. However,
when MDS patients were stratified according to the different
WHO subtypes a marked heterogeneity of slopes was evident
(Figure 1B). This suggested the relative preservation of the
homeostatic control by iron in certain MDS subtypes like RA
(Figure 2A), RARS and the 5q- syndrome (Figure 2B), as well as
the near complete loss of this mechanism in other MDS subtypes
like RAEB and CMML (Figure 2C). Noteworthy, comparing the
extremes of such models, i.e. RAEB and CMML versus RARS
and 5q-, a significant difference in hepcidin/ferritin slopes was
found (F = 8.684; P= 0.005).
Hepcidin determinants in MDS patients
To evaluate the independent determinants of serum hepcidin
levels in MDS patients we performed multivariate linear regression
models including possible confounders like age, gender, and
transfusion history (Table 3). Of note, serum ferritin levels
remained as significant predictors of serum hepcidin levels, as
did MDS subtypes. More precisely, when compared with RA
(considered as reference subtype), RARS (with a negative b-
coefficient), RAEB, and CMML (with a positive b-coefficient) were
independent predictors of serum hepcidin levels (Table 3, model
1). When CRP levels were added to the model, they also were
significant independent predictors of hepcidin levels along with
ferritin, while the MDS subtypes with high CRP levels (RAEB and
CMML) were no longer significant predictors, and the RARS
subtype remained significantly associated with hepcidin (Table 3,
model 2).
Discussion
Although percentage of marrow blasts, cytogenetic abnormal-
ities, and cytopenias remain the prognostic cornerstones in MDS,
recent data point to iron overload as an important contributing
factor. Transfusion dependency have been introduced in the
WHO based prognostic score [3], and serum ferritin levels have
been associated to either overall or leukemia-free survival [25].
Beyond the classic detrimental effect of cardiac siderosis [26],
other iron overload-related mechanisms have been proposed,
including an increased risk of infections, adverse effects on
hematopoietic stem cell transplantation, and a pro-oxidative state
promoting genomic instability and leukemic transformation [6].
Thus, elucidating the pathophysiology of iron overload beyond the
obvious role of RBC transfusions represents a relevant issue in
MDS patients, with possible therapeutic implications in selecting
those patients that may benefit at most from iron chelation therapy
[27–29]. As a general rule, an important factor in determining iron
toxicity is represented by the route by which the element enter the
body, which in turn is unable to excrete excess iron. The
parenteral route, i.e. through RBC transfusions, leads to
prominent macrophage iron overload that tends to be better
tolerated than the intestinal route, leading to prominent overload
in periportal hepatocytes and thereafter in other parenchymal cells
[30]. Given its pivotal role in orchestrating both iron absorption
and recycling from macrophages, hepcidin has been an attractive
candidate for studying perturbed iron homeostasis in MDS, but
few and contradictory data have been available until now. Winder
and colleagues [14] studied 16 MDS patients (4 RA, 3 RARS, 3
Table 1. General characteristics of the whole MDS population
as compared to a reference group with normal serum iron
indices and hepcidin.
Controls (n=54) MDS (n=113) P
Age (years) 34.8615.8 72.869.2 ,0.001
Male sex (%) 61.1 68.1 0.370
CRP (mg/l) 1.07 (0.93–1.23) 3.81(2.71–5.36) ,0.001
Ferritin* (mg/l) 79 (64–97) 515 (407–652) ,0.001
Hepcidin* (nM/l) 4.20 (3.53–5.00) 5.31 (3.98–7.08) 0.288
Hepcidin/Ferritin
Ratio*
52.94 (43.57–64.33) 10.10 (7.53–13.53) ,0.001
s-Iron (mg/dl) 100628 127659 ,0.001
s-Transferrin (g/l) 2.5160.37 2.0160.40 ,0.001
Transferrin
Saturation (%)
28.969.1 49.8627.4 ,0.001
*: geometric means with 95% Confidence Intervals between bracke.
doi:10.1371/journal.pone.0023109.t001
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RCMD, and 6 RAEB) 13 of them chronically transfused and
found undetectable or inappropriately low urinary hepcidin in
most of them. These Authors suggested that hepcidin suppression
through increased erythropoietic drive, and the ensuing increased
iron absorption may be generalized phenomena in MDS. Murphy
and colleagues [15] were unable to confirm these data in 17 low
grade MDS patients (8 transfusion dependent and 7 treated with
EPO), most of them showing normal, if not increased, urinary
hepcidin levels. Besides the very limited patients series, both these
studies suffered from methodological drawbacks, since they
employed first generation semi-quantitative assays of urinary
hepcidin that have been abandoned because of insufficient
precision [13]. To the best of our knowledge this is the largest
study on hepcidin levels in MDS conducted so far. Moreover, it
takes advantage from the use of a validated quantitative MS-based
assay [19], recently further improved [20]. Contrary to the prior
hypothesis of a generalized hepcidin suppression, the main
message from our data is that hepcidin production in MDS is
consistently heterogeneous, a condition that appears to parallel the
clinical and pathological heterogeneity of MDS by themselves.
This is also in agreement with in vitro experiments showing a
marked variability of sera from MDS patients in their ability to
suppress hepcidin in a hepatocyte cell line [31]. The spectrum of
hepcidin levels varied broadly from conditions with mean levels
less than a half of those in controls, like RARS, to other ones with
mean levels more than twice of controls, like RAEB and CMML
(Table 2). As regards to the homeostatic control of hepcidin by
iron, a similar heterogeneity was evident. Although the hepcidin/
ferritin ratio showed a generalized trend toward a relatively
inappropriate response, the homeostatic control by iron appeared
relatively conserved in MDS subtypes generally considered at low
risk (like RA, RARS and the 5q- syndrome), while it appeared
almost completely lost in conditions prominent dysmyelopoiesis
like RAEB and CMML. Since multivariate analyses showed that
CRP was also an independent determinant of hepcidin levels in
MDS along with ferritin and MDS subtypes, we could hypothesize
the observed hepcidin heterogeneity as the result of the relative
strength of opposing stimuli in different clinical and pathological
conditions (Figure 3). The main actors in this sense may be
represented by the suppressing effect from ineffective erythropoi-
esis, variably counterbalanced by the stimulating effects from
either increased iron stores or cytokines, of whom CRP is a
Table 2. Clinical and biochemical characteristics of MDS patients stratified according to WHO classification system.
RA
(n=31)
RARS
(n=9)
RCMD
(n=19)
RAEB
(n =32)
5q- syndrome
(n=7)
CMML
(n=7)
Unclass
(n=8) Pu
Age (years) 75.8610.3 73.467.7 73.767.1 70.267.6 71.4612.0 73.068.2 67.1613.0 0.163
Male sex (%) 61.3 44.4 73.7 78.1 57.1 85.7 62.5 0.397
CRP* (mg/l) 2.09
(1.07–4.10)
1.46
(0.36–5.56)
3.30
(1.37–7.97)
9.13
(5.41–15.39)
2.21
(0.53–9.13)
5.03
(0.19–129.90)
10.77
(5.16–22.48)
0.008
Ferritin* (mg/l) 368
(231–586)
725
(403–1305)
420
(230–768)
661
(461–947)
1364
(233–8001)
289
(130–646)
580
(135–2493)
0.104
Hepcidin* (nmol/l) 3.46
(2.06–5.81)
1.43
(0.51–4.03)
3.83
(1.85–7.96)
11.31
(7.38–17.32)
6.62
(1.26–34.84)
10.04
(2.10–48.00)
6.06
(1.18–31.27)
0.003
Hepcidin/Ferritin*
Ratio (nmol/mg61000)
9.39
(5.72–15.41)
1.97
(0.86–4.52)
9.13
(3.97–20.95)
16.69
(9.73–28.63)
4.85
(2.63–8.96)
34.68
(6.10–197.22)
10.45 (2.63–
41.45)
0.003
Hb (g/dl) 10.6262.08 10.1861.00 10.3161.40 9.0761.24 10.9062.30 9.4461.39 10.3961.87 0.008
Platelet count
(n. cell6109/l)
165.35699.01 411.786283.70 270.846641.14 91.53666.38 122.57671.82 82.57663.47 35.86632.58 0.051
LDH* (U/l) 321
(258–399)
304
(255–362)
371.85
(284–488)
280
(227–346)
283
(243–329)
403
(156–1042)
430
(128–1441)
0.393
NTBI (mM) 0.0161.15 1.5961.96 20.3261.25 0.0361.55 0.6561.82 0.1961.24 0.6061.92 0.058
s-Iron (mg/dl) 117653 153669 117655 131664 159667 126655 114643 0.441
s-Transferrin (g/l) 212638 180629 209646 191638 191641 209628 203650 0.219
Transferrin
saturation (%)
41.7623.4 68.4628.6 44.4623.9 51.9628.2 71.7635.2 48.9626.9 45.7626.1 0.048
GDF-15* (pg/ml) 3852
(2608–5687)
4793
(2144–10714)
4630
(2408–8904)
4846
(3284–7151)
5636
(1905–16677)
3938
(2225–6972)
3971
(1161–13585)
0.976
EPO* (U/l) 37.50
(14.56–96.54)
134.24
(51.61–349.15)
82.62
(35.96–189.62)
232.87
(149.55–362.64)
187.82
(46.04–766.24)
88.46
(17.75–440.76)
83.89
(11.29–623.34)
0.011
IPSS (%)
low 63.0 100.0 61.1 0.0 85.7 50.0 33.3
int-1 33.3 0.0 38.9 34.5 14.3 33.3 33.3
int-2 3.7 0.0 0.0 51.7 0.0 16.7 33.3 ,0.001
high 0.0 0.0 0.0 13.8 0.0 0.0 0.0
Transfused
patients (%)
29.6 33.3 27.8 56.3 33.3 57.1 50.0 0.303
u: by Analysis of Variance (ANOVA) or by x2-analysis, when indicated.
*: variables not normally distributed are expressed as geometric means with 95% CIs.
doi:10.1371/journal.pone.0023109.t002
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surrogate measure. RARS may represent the prototype of MDS
where the inhibition from the erythropoietic drive tends to prevail,
only partially balanced by the RBC transfusions, either directly or
indirectly through increased iron stores. This condition, charac-
terized by the lowest hepcidin/ferritin ratio, indeed showed also
the highest values of biochemical iron parameters indicating both
an expansion of the plasma iron pool through increased
absorption/recycling and parenchymal iron toxicity, like transfer-
rin saturation [32,33] and NTBI. Of note, studies from Mariani
and colleagues on hepatic hepcidin mRNA in two RARS patients
showed low levels consistent with this view [34]. At the other end
of the spectrum lies RAEB and CMML, where the highest levels of
both hepcidin/ferritin ratio and CRP may mirror hepcidin
stimulation through blast-derived cytokines that overcomes
controls by iron. Consistently with this hypothesis, both RAEB
and CMML lost their significant predictivity on hepcidin level in a
multivariate model adjusted with CRP levels. In this condition, the
relative excess of hepcidin could favour iron entrapment within
macrophages, limiting toxicity due to uncontrolled release of the
element into the plasma and redirection to parenchymal cells.
As regards to the hepcidin suppression from the erythropietic
drive, our results argue against a role of GDF-15 as the putative
mediator of this biological effect in MDS, at variance with what
observed in thalassemic syndromes [10]. GDF-15, also known as
bone morphogenetic protein (BMP) 14, is a secreted morphogen of
the transforming growth factor-beta super-family, conferring
signaling by activation of Smad 1/5/8 or mitogen-activated
protein kinase (p38-MAPK) [35]. It is highly expressed by
erythroid precursors in conditions of ineffective erythropoiesis,
but barely detectable in normal bone marrow [11]. In our series,
which again is the largest so far evaluating GDF-15 in MDS, mean
serum levels of this protein were near six to ten-fold higher than
reference values, with a relative homogeneity across different
MDS subtypes. Ramirez et al. [36] measured serum GDF-15 in a
specific study limited to twenty RARS patients, finding similar
levels (325461400 ng/ml) to our RARS series. Of note, this
fascinating and pleiotropic biomarker has been consistently
associated also to cardiovascular diseases in recent studies
[37,38], an issue that might merit further consideration in the
future within the specific context of MDS. Nevertheless, GDF-15
was not correlated at all with hepcidin levels in our series. The
apparent discrepancy of our results with those of Tanno and co-
workers in thalassemia [10] may be explained in terms of absolute
levels. Indeed, the GDF-15 levels reported in thalassemic patients
are consistently higher (up to more than 100,000 pg/ml) than
those found in our MDS series (mean levels near 4,500 pg/ml),
and in vitro studies have shown that significant hepcidin
suppression requires very high levels, i.e. no less than 5,000 pg/
ml, being still incomplete at the highest dose of 100,000 pg/ml
[10]. Recent expression studies in erythroblasts [39] have shown
that erythroid regulation of hepcidin may be an heterogeneous
phenomenon mediated by other molecules, i.e. TWSG1 (Twisted
Gastrulation) for which serum assay is not yet available. Further
studies are needed to clarify which mediators may play a role in
hepcidin suppression at least in certain MDS subtypes, particularly
in RARS [34]. The observation that iron biochemical parameters
Figure 1. Correlation plot between hepcidin and serum ferritin levels (logarithmic scale). (A) Controls versus all MDS patients. (B) MDS
patients stratified according to WHO classification.
doi:10.1371/journal.pone.0023109.g001
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are significantly higher than in controls also in our subset of non
transfused patients (Table S1), also reported by others [27] is a
further argument in favour of a certain degree of iron
hyperabsorption in MDS.
Our study suffers of several limitations that need to be
acknowledged. First, our considerations on hepcidin regulation
by iron rely on ferritin levels, which are known to be an imperfect
marker of iron stores [40]. Other measures of body iron stores
such as liver iron content (LIC) through Magnetic Resonance
(MR) [41,42] may be more accurate, considering that the ‘‘gold
standard’’ represented by liver biopsy is clearly unfeasible in
thrombocytopenic and generally elderly patients with several
Figure 2. Correlation plot between serum hepcidin and serum ferritin levels in different MDS subtypes as compared to controls
(logarithmic scale). (A) Controls versus RA. (B) Controls versus 5q- syndrome and RARS. (C) Controls versus CMML and RAEB.
doi:10.1371/journal.pone.0023109.g002
Table 3. Predictors of hepcidin levels in different linear regression models in MDS patients.
Model 1 1 Model 2 ‘
b-coefficient P b-coefficient P
Female sex 0.474 0.129 0.408 0.227
Age (years) 0.023 0.135 0.019 0.226
Ferritin (mg/l) 0.450 ,0.001 0.451 0.002
Myelodysplastic syndrome subtype *
RARS 21.245 0.019 21.181 0.024
RCMD 0.165 0.684 20.152 0.718
RAEB 1.015 0.008 0.711 0.087
5q- syndrome 0.321 0.616 0.205 0.746
CMML 1.282 0.028 0.784 0.235
Unclass. 0.502 0.367 0.270 0.648
Blood transfusion 20.181 0.538 0.066 0.830
CRP (mg/l) 0.210 0.020
*: considering RA as the reference group.
1: linear regression model adjusted for sex, age, ferritin levels, MDS type and history of blood transfusion (model 1).
‘: linear regression model adjusted for the above mentioned factors and CRP levels (model 2).
doi:10.1371/journal.pone.0023109.t003
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comorbidities like those with MDS. Nevertheless, recent data by
Armand and colleagues [43] indicate that serum ferritin is still an
acceptable marker of iron stores in MDS, since it showed a strong
and significant correlation (r = 0.75, P,0.001) with estimated LIC
by MR. Similarly, although our hepcidin assay is specific for the
25-mer bioactive isoform and has been clinically validated in other
settings [19,20,44,45], we have to recognize that we still lack a
gold standard for measuring this hormone in biological fluids [12].
Finally, the effect of inflammatory cytokines [46,47], which may
play a prominent role in certain MDS subtypes with excess
myeloblast activation, could be studied only indirectly, through a
surrogate like CRP.
Notwithstanding these limitations our results, if confirmed, may
be relevant for a better understanding of iron pathophysiology in
MDS. They point toward an heterogeneity that, like in any one
physiological situation, is determined by the relative strengths of
competing stimuli in different MDS subtypes (Figure 3), with
possible implications also at the individual level. This may help to
calibrate possible future therapeutic approaches in MDS patients
with either iron chelators [6,29] or hepcidin modulators [48,49].
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